Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Percutaneous Device Closure of PVL: An Alternative to Surgery

leak paravalvularParavalvular Leak (PVL) occurs in 5 to 17% of patients undergoing surgical valve replacement. Percutaneous device closure of PVL represents an alternative to repeat surgery.

 

All centers in UK and Ireland performing percutaneous PVL closure delivered their data to the UK PVL registry. Data were analyzed for factors associated with mortality and major cardiovascular events at follow up.

 

There were 308 percutaneous PVL closure procedures in 259 patients between 2004 and 2015 in 20 centers. Population mean age was 67±13 years and 28% were women.

 

Main indication for percutaneous PVL closure was:

  • Cardiac failure, 80% of cases.
  • Hemolysis, 16% of cases.

 

Implantation was successful in 91% of patients via:

  • Transradial (7%)
  • Transfemoral arterial (52%)
  • Transfemoral venous (33%)
  • Transapical (7%)

 

19% of patients required reintervention.

 

Intervened valves were:

  • Mitral, 44%
  • Aortic, 48%.
  • Both, 2%.
  • Pulmonic, 0.4%.
  • TAVR, 5%.

 

Periprocedural leak was severe in 61% and multiple in 37% of cases, and improved significantly after procedure (p<0.001), disappearing in 33.3%, or becoming mild (41.4%) or moderate residual leak (18.6%).

 

Patient functional class also improved significantly at median 110 day follow up.

 

In hospital death was:

  • Elective cases, 2.9%.
  • Urgent cases, 6.8%.
  • Emergency procedures, 50%.

 

[plain]

At follow up, mortality resulted 16%, vascular surgery 6% and late device embolization 0.4%. The mitral valve was associated with more adverse events compared to the rest of the valves.

[/plain]

 

Factors independently associated with death were:

  • Degree of persistent leak (HR 2.87; p=0.037).
  • Functional class at follow up (HR 2.00; p=0.015).
  • Baseline creatinine (HR 8.19; P=0.001).

 

Conclusion

Percutaneous paravalvular leak closure is effective and improves leak severity and symptom severity. Post procedural residual leak severity is independently associated with adverse events and death. Percutaneous PVL closure must be considered an alternative to repeat surgery.

 

Original Title: Percutaneous Device Closure of Paravalvular Leak. Combined Experience From the United Kingdom and Ireland.

Reference: Patrick A. Calvert et al. Circulation. 2016 Sep 27; 134(13):934-44.

 

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

We value your opinion. You are more than welcome to leave your comments, suggestions or questions here below.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...